1340: Rini B. Recent clinical development of dendritic cell-based immunotherapy
for prostate cancer. Expert Opin Biol Ther. 2004 Nov;4(11):1729-34. Review.
PubMed PMID: 15500401.


1341: Rini BI, Weinberg V, Fong L, Conry S, Hershberg RM, Small EJ. Combination
immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells
(provenge) plus bevacizumab in patients with serologic progression of prostate
cancer after definitive local therapy. Cancer. 2006 Jul 1;107(1):67-74. PubMed
PMID: 16736512.


1342: Rini BI, Small EJ. The potential for prostate cancer immunotherapy. Crit
Rev Oncol Hematol. 2003 Jun 27;46 Suppl:S117-25. Review. Erratum in: Crit Rev
Oncol Hematol. 2012 Sep;83(3):452. PubMed PMID: 12850532.


1343: Rini BI, Small EJ. Prostate cancer update. Curr Opin Oncol. 2002
May;14(3):286-91. Review. PubMed PMID: 11981273.


1344: Rini BI, Small EJ. Immunotherapy for prostate cancer. Curr Oncol Rep. 2001 
Sep;3(5):418-23. Review. PubMed PMID: 11489243.